Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an announcement.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced that Dr. Tian Wenzhi, the company’s executive director, CEO, and chairman, has increased his shareholding by purchasing 50,000 H shares on the open market. This purchase reflects Dr. Tian’s confidence in the company’s growth prospects, as he now holds 26.90% of the total issued share capital. The move is seen as a positive signal to shareholders and potential investors about the company’s future potential.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative cancer immunotherapies. The company operates within the healthcare industry, aiming to advance treatments that harness the body’s immune system to combat cancer.
Average Trading Volume: 3,700,347
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.1B
For a thorough assessment of 1541 stock, go to TipRanks’ Stock Analysis page.